vs

Side-by-side financial comparison of Metropolitan Bank Holding Corp. (MCB) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $88.5M, roughly 1.7× Metropolitan Bank Holding Corp.). Metropolitan Bank Holding Corp. runs the higher net margin — 35.5% vs -5.5%, a 41.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 25.4%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 14.3%).

Sandy Spring Bancorp, Inc. was a bank holding company headquartered in Olney, Maryland and operating in the Washington metropolitan area. In addition to banking services, the company offered commercial and personal lines of insurance, surety bonds, workers compensation insurance, and professional liability insurance protection as well as financial planning, wealth management, and asset management for high-net-worth individuals, businesses, and associations. In April 2025, the company was acqu...

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

MCB vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.7× larger
TARS
$151.7M
$88.5M
MCB
Growing faster (revenue YoY)
TARS
TARS
+103.0% gap
TARS
128.4%
25.4%
MCB
Higher net margin
MCB
MCB
41.0% more per $
MCB
35.5%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
14.3%
MCB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MCB
MCB
TARS
TARS
Revenue
$88.5M
$151.7M
Net Profit
$31.4M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
35.5%
-5.5%
Revenue YoY
25.4%
128.4%
Net Profit YoY
92.2%
63.8%
EPS (diluted)
$2.92
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MCB
MCB
TARS
TARS
Q1 26
$88.5M
Q4 25
$88.4M
$151.7M
Q3 25
$79.8M
$118.7M
Q2 25
$76.3M
$102.7M
Q1 25
$70.6M
$78.3M
Q4 24
$71.0M
$66.4M
Q3 24
$71.5M
$48.1M
Q2 24
$67.7M
$40.8M
Net Profit
MCB
MCB
TARS
TARS
Q1 26
$31.4M
Q4 25
$28.9M
$-8.4M
Q3 25
$7.1M
$-12.6M
Q2 25
$18.8M
$-20.3M
Q1 25
$16.4M
$-25.1M
Q4 24
$21.4M
$-23.1M
Q3 24
$12.3M
$-23.4M
Q2 24
$16.8M
$-33.3M
Operating Margin
MCB
MCB
TARS
TARS
Q1 26
Q4 25
46.6%
-5.3%
Q3 25
12.8%
-12.2%
Q2 25
35.1%
-21.6%
Q1 25
33.1%
-33.5%
Q4 24
44.1%
-36.8%
Q3 24
24.6%
-52.3%
Q2 24
35.3%
-81.6%
Net Margin
MCB
MCB
TARS
TARS
Q1 26
35.5%
Q4 25
32.6%
-5.5%
Q3 25
8.9%
-10.6%
Q2 25
24.6%
-19.8%
Q1 25
23.2%
-32.1%
Q4 24
30.2%
-34.8%
Q3 24
17.2%
-48.7%
Q2 24
24.8%
-81.6%
EPS (diluted)
MCB
MCB
TARS
TARS
Q1 26
$2.92
Q4 25
$2.74
$-0.17
Q3 25
$0.67
$-0.30
Q2 25
$1.76
$-0.48
Q1 25
$1.45
$-0.64
Q4 24
$1.89
$-0.57
Q3 24
$1.08
$-0.61
Q2 24
$1.50
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MCB
MCB
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$948.3M
$343.4M
Total Assets
$8.8B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MCB
MCB
TARS
TARS
Q1 26
Q4 25
$393.6M
$417.3M
Q3 25
$385.9M
$401.8M
Q2 25
$152.5M
$381.1M
Q1 25
$196.5M
$407.9M
Q4 24
$200.3M
$291.4M
Q3 24
$318.5M
$317.0M
Q2 24
$244.7M
$323.6M
Total Debt
MCB
MCB
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
MCB
MCB
TARS
TARS
Q1 26
$948.3M
Q4 25
$743.1M
$343.4M
Q3 25
$732.0M
$335.1M
Q2 25
$723.0M
$332.6M
Q1 25
$737.8M
$342.5M
Q4 24
$729.8M
$224.5M
Q3 24
$715.2M
$237.5M
Q2 24
$692.4M
$252.2M
Total Assets
MCB
MCB
TARS
TARS
Q1 26
$8.8B
Q4 25
$8.3B
$562.2M
Q3 25
$8.2B
$534.6M
Q2 25
$7.9B
$495.0M
Q1 25
$7.6B
$500.8M
Q4 24
$7.3B
$377.0M
Q3 24
$7.4B
$376.3M
Q2 24
$7.3B
$376.8M
Debt / Equity
MCB
MCB
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MCB
MCB
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MCB
MCB
TARS
TARS
Q1 26
Q4 25
$88.7M
$19.3M
Q3 25
$31.8M
$18.3M
Q2 25
$18.4M
$-29.4M
Q1 25
$7.8M
$-20.7M
Q4 24
$148.5M
$-22.2M
Q3 24
$4.8M
$-8.7M
Q2 24
$35.3M
$-14.4M
Free Cash Flow
MCB
MCB
TARS
TARS
Q1 26
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
FCF Margin
MCB
MCB
TARS
TARS
Q1 26
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Capex Intensity
MCB
MCB
TARS
TARS
Q1 26
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Cash Conversion
MCB
MCB
TARS
TARS
Q1 26
Q4 25
3.07×
Q3 25
4.47×
Q2 25
0.98×
Q1 25
0.47×
Q4 24
6.93×
Q3 24
0.39×
Q2 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons